Raphael Pharmaceutical (RAPH) Research & Development (2020 - 2024)
Raphael Pharmaceutical (RAPH) reported Research & Development of $211000.0 for Q4 2024, up 160.63% on a YoY basis from $80957.0 in Q1 2024, and up 30.25% sequentially from $162000.0 in Q3 2024.
Raphael Pharmaceutical (RAPH) Research & Development (2020 - 2024) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 5 years of Research & Development data on file, last reported at $211000.0 in Q4 2024.
- For the quarter ending Q4 2024, Research & Development rose 160.63% year-over-year to $211000.0; the trailing twelve-month figure through Dec 2024 stood at $776000.0 (up 36.38% YoY), and the FY2025 full-year result was $631000.0, down 18.69% from the prior year.
- Research & Development improved to $211000.0 in Q4 2024, from $162000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $676000.0 in Q4 2022 to a low of -$348000.0 in Q4 2023.
- A 5-year average of $207000.0 and a median of $211000.0 in 2024 frame the typical range for Research & Development.
- Peak annual rise in Research & Development reached 248.81% in 2023, while the deepest fall reached 151.48% in 2023.
- Tracing RAPH's Research & Development over 5 years: stood at $220000.0 in 2020, then advanced by 1.82% to $224000.0 in 2021, then jumped by 201.79% to $676000.0 in 2022, then slumped by 151.48% to -$348000.0 in 2023, then surged by 160.63% to $211000.0 in 2024.
- Business Quant data shows RAPH's Research & Development at $211000.0 in Q4 2024, $162000.0 in Q3 2024, and $24000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 696.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 180.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 7.37 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 138.20 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 248.60 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 296.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 97.00 Mn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 211,000.00 |
| Sep 30, 2024 | 162,000.00 |
| Jun 30, 2024 | 24,000.00 |
| Mar 31, 2024 | 379,000.00 |
| Dec 31, 2023 | -348,000.00 |
| Sep 30, 2023 | 510,000.00 |
| Jun 30, 2023 | 293,000.00 |
| Mar 31, 2023 | 114,000.00 |
| Dec 31, 2022 | 676,000.00 |
| Sep 30, 2022 | 332,000.00 |
| Jun 30, 2022 | 84,000.00 |
| Mar 31, 2022 | 86,000.00 |
| Dec 31, 2021 | 224,000.00 |
| Sep 30, 2021 | 161,000.00 |
| Jun 30, 2021 | 222,000.00 |
| Mar 31, 2021 | 169,000.00 |
| Dec 31, 2020 | 220,000.00 |